Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1695 clinical trials
Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI

Prospective data for self-expanding devices are required to compare the extent of paravalvular leakage as a result of device design. Grading paravalvular leakage after TAVI is difficult. Echocardiography and angiography systematically underestimate paravalvular leakage (PVL) as compared to cardiac MRI.

regurgitation
transcatheter aortic valve implantation
thoracic surgery
stenosis
tavi
  • 0 views
  • 16 Feb, 2024
  • 1 location
Role of CEUS as a Secondary Diagnostic Modality

To determine the role of contrast-enhanced ultrasound (CEUS) as a second-line imaging modality after gadoxetate-enhanced MRI (Gd-EOB-MRI) for identifying hepatocellular carcinoma (HCC) among at-risks observations.

hepatocellular carcinoma
carcinoma
contrast-enhanced ultrasound
  • 0 views
  • 05 Aug, 2020
As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period

This study will evaluate the efficacy of as-needed Budesonide/formoterol Turbuhaler 160/4.5 g/d in the period of step down in well controlled asthmatic patient comparing with standard maintenance therapy in step-2 management in asthma guildeline which is low dose inhaled corticosteroid.

montelukast
corticosteroids
eosinophil count
maintenance therapy
fractional exhaled nitric oxide
  • 0 views
  • 16 Feb, 2024
  • 1 location
Cortico-Spinal tDCS as Rehabilitative Intervention in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. The disorder causes muscle weakness and atrophy throughout the body due to the degeneration of the upper and lower motor …

motor neuron disease
primary lateral sclerosis
excitability
neurodegenerative disorders
amyotrophic lateral sclerosis
  • 0 views
  • 16 Feb, 2024
  • 1 location
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC. Investigator hypothesized that lenvatinib may be an effective conversion treatment for HCC, and preoperative treatment with lenvatinib can improve resectability in …

  • 0 views
  • 16 Feb, 2024
  • 4 locations
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

A recent randomized trial has proved the efficacy of Rituximab, a monoclonal anti-CD20 antibody against B-lymphocytes, as an efficacious therapy for pemphigus. Early use of rituximab was associated with better clinical outcomes, hence combination treatment of rituximab and intravenous immunoglobulins (IVIG) has shown to be effective for refractory pemphigus cases …

intravenous immunoglobulin
acantholysis
pemphigus
rituximab
anti-cd20 antibody
  • 0 views
  • 16 Feb, 2024
  • 1 location
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.

amlodipine
moxonidine
ace inhibitor
amlodipine 5 mg
body mass index
  • 0 views
  • 16 Feb, 2024
  • 1 location
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia.

rituximab
antibody therapy
immunochemotherapy
b-cell lymphoma
monoclonal protein
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Carfilzomib Daratumumab Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Carfilzomib in combination with lenalidomide, daratumumab and dexamethasone (KRDd) can induce profound clinical responses. The investigators want to observe the effectiveness of the quadruple therapy of carfilzomib, lenalidomide, daratumumab and dexamethasone on patients receiving 8 cycles of KRDd with autologous stem cell transplantation versus patients with 8 cycles of KRDd …

lenalidomide
daratumumab
anemia
autologous hematopoietic stem cell transplant
dexamethasone
  • 0 views
  • 16 Feb, 2024
  • 1 location
Mobile App as a Guide to Exercises for Patients With Chronic Stroke

Introduction: Stroke continues to be one of the leading causes of disability in the Spanish adult population with the presentation of impairments such as alteration of mobility and a consequent reduction in quality of life. These sequelae, generally chronic, generates a significant expense and saturation of social and health services.

hemiplegia or hemiparesis
hemiparesis
stroke
hemiplegia
physical rehabilitation
  • 0 views
  • 16 Feb, 2024
  • 1 location